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ABSTRACT
Introduction: Interest in the possibility of 
certain insulin treatments having the potential 
to modify cancer development and prognosis 
was reawakened in 2009, following publication 
of several epidemiological studies addressing 
this issue. This interest extends to how diabetes 
itself and cancer might be linked, and makes 
desirable an exchange of expert views and 
knowledge to enhance understanding in this 
subject among those treating diabetes and 
cancer, or those developing diabetes therapies. 
Methods: A European meeting was convened 
with participants invited based on known 
relevant interests in endocrinology, oncology, 
epidemiology, and insulin analog design and 
investigation. Experts in these fields were 
invited to present on relevant topics, with 
open discussions held after each presentation. 
Results: Concern over the potential mitogenic 
properties of certain insulin analogs has 
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arisen from some (but not all) epidemiological 
studies, although confounding factors 
render interpretation controversial. Future 
epidemiological studies are likely to strengthen 
confidence in drawing conclusions. Meanwhile, 
pharmacological studies, and a consideration 
of cancer pathophysiology, implicate increased 
insulin-like growth factor-1 receptor affinity, 
and/or deranged insulin receptor interaction/
signaling properties as possible a priori causes 
for concern with some insulin analogs. Again, 
interpretation of the body of pharmacological 
evidence is confounded by the array of test 
systems and methodologies used, and by studies 
frequently succumbing to methodological 
pitfalls. Reassuringly, most available insulin 
analogs do not differ in their receptor interaction 
response profile to human insulin, and for 
those that do there are reasons to question 
any potential clinical relevance. Nevertheless, 
it is desirable that new experimental models 
are devised that can better determine the 
likely clinical consequences of any variance 
in receptor response profile versus human 
insulin. Conclusion: More data are required 
to increase our understanding of this issue. To 
facilitate and disseminate such understanding, 
close cooperation and communication between 
diabetologists, epidemiologists, oncologists, and 
insulin engineers will be essential.
Keywords: cancer, detemir, diabetes, glargine, 
insulin, insulin-like growth factor, insulin 
receptor, mitogenicity
INTRODUCTION 
Stephen Gough, Meeting Chairman
The disclosure of data in June 2009 of four 
epidemiological studies,1-4 three of which 
reported a potential link between the use 
of insulin glargine and an increased risk of 
cancer,1,3,4 has provoked ongoing debate about 
the long-term clinical safety of insulin analogs. 
This debate arises because of anomalies and 
confounding factors in these four retrospective 
studies that cast doubt on the conclusions 
reached. Type 2 diabetes mellitus (T2DM) is 
itself associated with an increased incidence and 
risk of mortality from a range of cancers,5,6 and 
associated comorbidities and lifestyle factors, 
such as obesity and physical inactivity, are also 
associated with increased risk.7 Furthermore, 
different diabetes treatments (which are often 
used concomitantly) can modify the risk of 
developing cancer (with metformin, for example, 
providing a protective effect8,9) and insulins 
and sulfonylureas potentially promoting tumor 
growth.10,11 This intricate web of interactions 
makes interpretation of epidemiologic studies 
difficult and, perhaps unsurprisingly given 
the controversial and far-reaching nature of 
the topic, the 2009 Diabetologia papers drew 
appropriate criticism over methodology.12
In response, the European Medicines 
Agency has now listed insulin analog and 
cancer safety as one of its priorities for 
drug safety research in 2011.13 The insulin 
manufacturer Novo Nordisk (Copenhagen, 
Denmark) is one of several companies that has 
an interest in this field, and in ensuring that 
the molecular safety profile of insulin analog 
products is both satisfactory and established 
through appropriate scientific study. Novo 
Nordisk, therefore, convened and sponsored 
a meeting of individuals with expertise and/
or research interests in this area to enable 
free exchange of views and information. This 
group was designated ‘The European Insulin 
Safety Consensus Panel,’ as it was hoped that, 
in addition to providing a timely update on 
results from recent and ongoing studies, 
the attendees would assess the possibility of 
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reaching consensus on how to interpret the 
available data and the next steps required in 
future research. The panel members listed as 
authors gave presentations at the meeting 
on topics suggested by the sponsor, although 
the content of these presentations was not 
influenced by the sponsor. Here, the views and 
data presented, and salient discussion points 
arising, are summarized. The subheadings 
below reflect the titles of the presentations 
given, but in the interest of keeping 
topics coherent for the reader, some slight 
modifications have been made in this report 
to the original sequence of presentations. 
THE INSULIN AND CANCER STORY 
- HOW IT ALL STARTED 
Christopher Poole
How diabetes and its treatment affect cancer risk 
and outcome has been studied steadily over the 
last decade (driven primarily by oncologists). 
The possibility that insulin analogs could affect 
cancer development differently to human 
insulin was first realized with the development 
of the X10 analog, as described below. However, 
four epidemiological papers published in 
Diabetologia in 20091-4 have greatly increased 
awareness among the diabetes community 
that widely used treatments might influence 
patients’ risk of cancer. As a result, publications 
on the subject in diabetes journals have 
multiplied over the last year, and the issue has 
drawn the attention of many diabetologists for 
the first time. The story of these publications 
in Diabetologia was somewhat controversial, 
and there remains disagreement about how 
best to interpret the data. Indeed, the original 
German study submission by Hemkens and 
colleagues1 presented a challenge to the journal 
referees (due to methodological concerns) and 
gave the Diabetologia editors a moral dilemma, 
which they resolved by commissioning three 
validation studies using databases in the UK, 
Sweden, and Scotland.2-4
In brief, the Hemkens study described a 
crude incidence of cancer that was higher with 
human insulin than with insulin analogs.1 After 
adjusting for dose, however, insulin glargine 
was associated with an increased incidence of all 
cancers. Conversely, short-acting insulin analogs 
did not appear to be associated with excess 
cancer or mortality. The UK study by Currie and 
colleagues2 found that insulin and sulfonylurea 
therapy was associated with an increase in risk 
of pancreatic and colorectal cancer, but not of 
breast cancer. Combination therapy involving 
metformin protected against the increased 
cancer risk with these therapies. There was no 
difference in cancer risk between specific insulin 
regimens in this study. The Swedish study3
found that women using insulin glargine alone 
(ie, without other insulin products, although not 
necessarily as their sole diabetes therapy) had an 
increased incidence of breast cancer, but other 
malignancies did not appear to be affected by 
glargine. The Scottish study4 found no difference 
in total or site-specific cancer in those exposed 
or not exposed to insulin glargine. However, 
patients exposed to glargine alone had a higher 
rate of all cancers, including breast cancer.
Such epidemiological studies are always 
open to competing ways of interpretation, 
but various methodological weaknesses in the 
original Hemkens study should be considered. 
First, there was no differentiation made between 
type 1 (T1) and T2DM, and no adjustment made 
for body mass index or endogenous insulin 
status; hence the comparator cohorts are likely to 
have had different demographics. This problem 
is also highly likely to pertain to the analysis 
of ‘glargine alone versus any other insulin 
regimens’ used in the Scottish4 and Swedish3
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studies. Second, in the primary analysis of the 
German study,1 glargine carried a lower relative 
risk than other insulins, which reversed only after 
adjustment for dose. It is usual practice to adjust 
for potential confounding factors to see if an 
association found with raw data disappears after 
adjustment, but not to identify new associations. 
With the latter approach, any result might be 
claimed if repeated adjustments are made until 
an expected finding is seen. Adjusting, it should 
be remembered, is not the same as controlling. 
Third, when data were stratified by three dose 
groups, a U-shaped curve was observed, which 
seems implausible, and the follow-up period 
(1.3 years) seems very short for a cancer risk 
difference to manifest. Finally, the a posteriori
treatment group allocation based on follow-up 
information and the use of mean insulin doses 
observed during the follow-up period, as baseline 
covariates in a survival analysis, are fundamental 
errors in an epidemiological analysis. 
Discussion Points Arising
Future epidemiologic studies would ideally take 
account of insulin resistance as a confounding 
factor, as high insulin doses are typically 
associated with major insulin resistance. In 
practice, however, this would be difficult to do.
The data from the Hemkens study might 
have been more convincing had the approach 
been to compare glargine-only to Neutral 
Protamine Hagedorn (NPH)-only insulin 
therapy. However, there was some logic to the 
approach taken, as it reflected the historical use 
of insulin in T2DM in Germany: the tradition 
has been to use supplementary mealtime 
insulin therapy, with basal insulin plus oral 
antidiabetic drug therapy only recently gaining 
favor as an alternative regimen. 
There are at least three possible explanations 
as to why an elevated cancer risk might manifest 
so soon after insulin initiation. First, it is possible 
that the sudden rise in insulinemia activates 
latent insulin-sensitive neoplastic loci. Second, 
an alternative (but not mutually exclusive) 
possibility is reverse causality, ie, a pre-existing 
tumor that affects glycemia might lead to 
insulin initiation. In this respect, diabetes and 
liver cancer are certainly related via hepatitis 
C infection. A third possible reason why an 
excess of cancer appears to manifest ‘early’ 
in the natural history of diabetes is that any 
potential excess of later-life cancer is subjugated 
by cardiovascular mortality. 
Ideally, future epidemiologic studies should 
be based on a consensus of good methodology 
to cover: 
•	 adequate accounting for competing cancer 
risk factors
•	 comparisons based on well-matched groups 
with equivalent exposures 
•	 the use of agreed covariates in statistical 
analyses
•	 cancer heterogeneity. 
RECENT EPIDEMIOLOGIC 
FINDINGS FROM ITALY AND 
FINLAND ON THE RISK OF CANCER 
ASSOCIATED WITH DIABETES AND 
HYPERGLYCEMIA 
Edoardo Mannucci ∙ Jaakko Tuomilehto 
In an effort to address many of the confounders 
of the 2009 Diabetologia publications, an Italian 
study was conducted that employed a nested 
case-control design.14 This considered long-term 
follow-up data (6.3 years) from a consecutive 
series of 1340 out-patients with T2DM 
initiating insulin therapy and with no previous 
malignancies. Incident cancer cases (n=112) 
were identified through hospital discharge 
records and death registries. Comparisons were 
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made between cases and matched controls 
to identify predictors of incident cancer. The 
use of glargine was not found to be higher in 
cases than controls, but cases using glargine 
were taking higher doses than controls using 
glargine; a relationship that did not apply to 
other insulins. After adjusting for comorbidities, 
other types of insulin, and metformin exposure, 
there was an increased risk for incident cancer 
in patients taking glargine at doses ≥0.3 IU/kg/
day (odds ratio: 5.43 [95% confidence interval: 
2.18-13.53], P<0.001), both when taking the 
overall observation period into consideration and 
when excluding all incident cancers from the first 
year of glargine treatment. Metformin was under-
represented in cases versus controls, supporting 
other work suggesting a protective effect.2,15,16
Another study, yet to be published, that 
offers considerable promise for informative 
data is being conducted in Finland and involves 
computer linkage between the entire national 
diabetes database (all patients diagnosed between 
1988-2007), and cancer and other registry 
databases. Age at diagnosis and drug therapy 
will allow a reasonably reliable classification 
into T1DM and T2DM categories. The number 
of observed cancer cases can be compared with 
national averages to generate standardized 
incidence ratios, stratifying patients (including 
children) into 5-year age interval groups, and 
calculating person-years of risk for calendar 
periods between 1988 and 2008. Preliminary 
analyses of the data reveal significant increases 
(of more than 10%) in the overall cancer risk 
of people with diabetes versus the background 
population. More than 20 different site-specific 
cancers were also found to be significantly 
increased in people with diabetes. However, 
one issue, highlighted by a recent Diabetes 
Epidemiology: Collaborative analysis Of 
Diagnostic criteria in Europe (DECODE) group 
study,17 is that cancer risk associated with 
diabetes may be underestimated due to the 
risk extending ‘down’ into the undiagnosed 
hyperglycemic population. Incident cancers in 
these individuals are currently categorized as 
occurring in the ‘normal’ population. 
Discussion Points Arising
The Finnish study, alone or in combination with 
similar data from other countries, may be of 
sufficient size and scope to enable construction 
of matched groups to study outcomes by 
exposure to different diabetes therapies, to 
undertake time-to-event analyses, to investigate 
the incidences of subtypes of breast cancer, and 
to investigate the influence of a family history 
of cancer.
Frequent contact with care providers might 
inflate the cancer diagnosis rate in people with 
diabetes. It could be useful to make comparisons 
with cohorts of people without diabetes, but 
who also have regular contact with carers.
There is a paradox that prostate cancer 
seems to be less frequent in men with diabetes 
than in the background population. Possible 
explanations include hypogonadism associated 
with obesity and the difficulty of palpating a 
prostate lesion in an obese man. This finding 
from several epidemiologic studies is supported 
by a reduction in the diagnostic prostate-specific 
antigen in men with T2DM.18,19
THE IGF SYSTEM: OVERVIEW OF ITS 
ROLE IN TUMORIGENESIS 
Matthias Weber
The mitogenic influence of insulin mediated via 
the insulin-like growth factor (IGF) system is 
currently considered as one of the most plausible 
mechanisms to explain a link between insulin 
use and cancer risk. This system encompasses a 
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complex regulatory network that includes two 
peptide growth factors (IGF-1 and IGF-2) with 
homologies to insulin, cell-surface receptors for 
these peptides (including IGF-1R and IGF-2R), 
and six high-affinity IGF binding proteins 
(IGFBP), to which most circulating IGF is bound. 
In mammals, IGF-1 is produced in large amounts 
in the liver in response to pituitary growth 
hormone (GH). It is also produced locally as 
a paracrine/autocrine growth factor. IGF-1 
interacts with IGF-1R to stimulate cell growth 
and mitosis, and IGF-2 has a high affinity for 
both IGF receptors and acts as an important 
fetal growth factor. IGF-2R does not appear to 
produce a signal, but instead acts to degrade 
IGF-2 and as a tumor suppressor. 
The IGF system appears to have evolved 
to regulate somatic growth of the organism, 
coupled tightly to nutritional status, and in many 
animals this regulation extends to reproduction 
and longevity.20-23 Indeed, both calorie restriction 
and disruption of IGF signaling extend lifespan 
in many species, ranging from worms and flies 
through to mammals.20,21 Interestingly, mutations 
in IGF-1R (resulting in decreased functional 
activity) are more prevalent in centenarian 
humans.24 The importance of the IGF system 
for survival is demonstrated by the fact that it 
is highly conserved between species throughout 
evolution, particularly the gene encoding IGF-1.24
However, what role does the IGF system play 
in cancer? Various epidemiologic studies have 
shown a correlation between high circulating 
levels of IGF-1 and an increased risk of breast, 
colorectal, lung, and prostate cancer.25-28
Conversely, there tend to be negative associations 
between serum IGFBP-3 and cancer risk.26-28 IGFBP 
affect signaling by sequestering IGFs (or, in some 
cases, presenting IGFs to receptors), which are 
themselves regulated by IGFBP-proteases. IGFBP 
may also bind cell surface receptors to directly 
affect cellular processes.29
Acromegaly provides a potential model 
to study the influence of the IGF system on 
prognosis, as IGF-1 levels are raised in response to 
GH hypersecretion. The available epidemiologic 
data suggest only a small excess of cancer in 
people with this condition, compared with the 
general population.30 This observation does not 
implicate IGF as being carcinogenic, although it 
may drive the growth of pre-existing, subclinical 
tumors. This hypothesis is supported by the 
observations that (along with overexpression of 
IGF-2), many cancers over-express intact IGF-1R, 
and that inactivation of the IGF-1R, for example 
after transfection of a dominant negative IGF-1R, 
can retard cancer cell growth experimentally.31
Other observations, however, suggest that 
IGF can malignantly transform some cells: 
fibroblasts require the presence of intact 
IGF-1R to undergo malignant transformation 
via the transforming action of oncogenes.32
Also, the over-expression of IGF-1R can induce 
malignant transformation in some cell models, 
eg, NIH 3T3 cells.33
Cancer cells frequently over-express IGF-1R, 
IGF-2, and (sometimes) IGFBP-2. It is thought 
that these abnormalities usually occur late in the 
natural history of neoplasia and accelerate the 
growth of transformed cells. Therefore, various 
agents that inhibit IGF-1R signaling are in 
development as putative anticancer therapies.34
While many tumor types over-express IGF-1R, 
others also over-express insulin receptor (IR), and 
over-expression of each receptor type in most 
cases is predictive of poor prognosis.35 Although 
these receptors exhibit distinct roles in normal 
physiology (IR activation resulting primarily 
in metabolic outcomes and IGF-1R activation 
leading mainly to mitogenic outcomes) there is 
some overlap in the downstream processes they 
are able to effect. There is also some binding 
affinity between the insulin molecule and 
IGF-1R (and between IGF-1 and IR), albeit that 
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each ligand has a much higher affinity for its 
own receptor. It is therefore unsurprising that 
insulin can also influence tumor development 
and progression; indeed, mitogenic effects with 
insulin were first demonstrated in vitro in the 
1950s.36,37 Although the mitogenic potency of 
insulin is much less than that of IGF-1, insulin 
can alter cell responses to cellular growth factors 
via activation of the farnesyltransferase pathway, 
enhancing the mitogenic potential of, among 
other growth factors, IGF-1.38 Furthermore, 
hyperinsulinemia has been associated with 
increased tumor proliferation, and the growth of 
some human breast cancer cells has been shown 
to be responsive to insulin.39,40
The IR exists as two isoforms, and cancer 
cells tend to express the IR-A isoform, which 
is normally characteristic of placental and 
fetal tissues. IR-A also has a high affinity for 
IGF-2 and can evoke mitogenic responses. IR-A 
expression tends to occur late in the natural 
history of tumors so is unlikely to be causative, 
but it might be permissive in tumor growth. 
To complicate matters further, cancer cells can 
also express IR/IGF-1R hybrid receptors and the 
relevant ligands (insulin, IGF-1, IGF-2) have 
some affinity for these hybrids too, which can 
again evoke mitogenic responses. 
Discussion Points Arising
Changes in insulin/IGF-1 function at a cellular 
level may offer a survival advantage to latent 
neoplasms by facilitating growth signal self-
sufficiency and resistance to apoptosis.41 It 
is also possible that the signaling of IR and 
IGF-1R might be modified by the metabolic 
conditions associated with diabetes and its 
therapy, such as periods of hypoglycemia. 
Similarly, hyperinsulinemia has an important 
influence on cancer risk and it is possible that 
IR-mediated metabolic pathways (and tissues) 
become insulin resistant in diabetes, whereas 
mitogenic pathways remain insulin sensitive. 
Furthermore, the role of IR/IGF-1R hybrids and 
the fetal isoform of IR in tumorigenesis need to 
be elucidated in future studies.
INSULIN ANALOGS, IGF-1R, AND 
STEM-LIKE CANCER CELLS 
Cristóbal Belda-Iniesta
Relevant to the consideration of insulin analog 
development is the fact that genes encoding the 
IGF-1 and insulin molecules are homologous, 
having arisen, it is thought, from a common 
ancestor.42 Consequently, human IGF-1 and 
insulin molecules share 45% amino acid 
homology. There is also considerable (~60%) 
homology between IR and IGF-1R. IGF-1 differs 
from insulin by an additional three amino 
acid residues at the B terminus (two arginines 
interspersed with a tyrosine) that introduce a 
positive charge. This draws the peptide into the 
negatively charged external binding pocket of 
the IGF-1R dimer. 
Given these close similarities, it is possible that 
modified insulin molecules could inadvertently 
have increased IGF-1R affinity. This is of 
potential clinical concern because of the tumor-
promoting (transformation and mitosis) effects 
mediated via IGF-1R elaborated in the previous 
presentation. IGF-1R activation is also associated 
with poorer cancer prognosis,43,44 increased rate 
of metastasis,45 and reduced responsiveness 
to radiotherapy,46,47 chemotherapy,43,48-50 and 
targeted therapies against the endothelial 
growth factor receptor.49,50
However, even if an analog has increased 
IGF-1R affinity, it does not automatically follow 
that this will be of clinical consequence. Firstly, 
there is the consideration that the absolute 
IGF-1R affinity relative to human insulin may 
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still be orders of magnitude lower than that of 
IGF-1 itself. The proliferative potential of such an 
analog may manifest when added in isolation to 
the culture medium of cells expressing IGF-1R, 
but such test systems could be considered ‘worst 
case scenario,’ as in vivo cancer cells are likely to 
express a mixture of receptor types and to meet 
a host of potential ligands including native 
IGF-1. The question arises of whether an 
analog with an elevated IGF-1R binding affinity 
would even reach cancer cells in sufficient 
concentrations to evoke proliferative responses, 
and whether such a signal would be ‘drowned 
out’ by endogenous IGF-1 anyway. Against this 
possibility is the fact that most circulating IGF-1 
is bound by IGFBP, and hence is biologically 
inactive. It is known that interstitial fluid pressure 
can be increased in tumor tissue compared with 
healthy tissue, thereby presenting a potential 
barrier restricting the access of circulating peptide 
hormones; both exogenous and endogenous.51
A further potential barrier may be presented 
by increased local collagen deposition. Thus, 
the endocrine environment may be of little 
importance compared with paracrine/autocrine 
responses within the developing tumor.
Another area of uncertainty for consideration 
is that of insulin analog metabolism. Insulin 
glargine incorporates two additional arginine 
residues at the B chain terminus, giving this 
region a positive charge, as is the case with 
IGF-1, and hence an increased affinity for IGF-1R. 
However, these residues can be enzymatically 
cleaved to produce two metabolites that do not 
have elevated IGF-1R affinity.52
In summary, IGF-1R can be considered 
a proto-oncogene and the inhibition of its 
signaling is now being studied as a therapeutic 
target in oncology. Despite some continuing 
uncertainties, there are therefore theoretical 
reasons for avoiding the development 
of insulin analogs with increased IGF-1R 
affinity based on modifications that are not 
enzymatically cleaved.
Discussion Points Arising
It was noted that the evidence that insulin 
glargine is metabolized comes from an ex vivo
study52 in which glargine was cultured with 
human blood for 30 minutes; much longer than 
the circulating half-life of the drug. Therefore, 
speculation remains as to whether a high 
percentage of glargine is metabolized in vivo. Of 
potential relevance here, Mayer and Chantelau53
added serum taken from patients treated with 
glargine to the culture medium of human breast 
cancer cells. In contrast to the serum of patients 
treated with NPH or insulin detemir, this was 
associated with a statistically significant 11% 
increase in proliferative response, but it should 
be noted that this study was not controlled for 
other components of human sera.
The issue was raised of the timescale, over 
which endocrine factors can influence cancer 
risk manifestation, and it was noted that 
the increased risks associated with hormone 
replacement therapy and the contraceptive pill 
normalize within 5 years of discontinuation. 
This suggests that endocrine influences on 
cancer incidence can occur in shorter time-scales 
than popularly appreciated. 
INSULIN MODIFICATION 
AND CONSEQUENCES FOR 
MITOGENICITY 
David Russell-Jones 
The realization that artificial modifications of 
the insulin molecule could sometimes lead to 
unintended increases in mitogenic potential (ie, 
the ability of the analog to stimulate cell division 
at least in vitro to a greater extent than human 
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insulin) dates back to the early 1990s when the 
insulin manufacturer Novo Nordisk developed 
a rapid-acting insulin analog called ‘X10’. This 
monomeric analog differed from human insulin 
by a single amino acid substitution, with the 
B10 histidine residue replaced with aspartic 
acid, to create a peptide that occurs rarely as 
a natural mutation.54,55 In pharmacokinetic/
pharmacodynamic studies, subcutaneously 
injected X10 more closely mimicked the natural 
prandial insulin response than soluble human 
insulin,56 but clinical development was terminated 
when toxicology studies revealed a dose-related 
increase in incident mammary tumors in female 
Sprague-Dawley rats.57 This then prompted a 
series of studies designed to identify the possible 
mechanism(s) responsible, and X10 was found 
to differ from human insulin in two important 
pharmacological properties (Figure 1).58,59 Firstly, 
X10 was found to bind59,60 and activate61 IGF-1R 
with greater potency than that of human insulin. 
Thus, the ratio of binding affinity for IGF-1R 
relative to IR was increased about four-fold. 
Secondly, X10 occupied (and stimulated) the IR 
for a longer period of time than human insulin 
before internalization and degradation of the 
ligand-receptor complex, ie, X10 had a reduced 
IR ‘off-rate’.58,62,63 Importantly, by constructing a 
series of experimental insulin analogs that varied 
in each of these two properties, it was shown 
that the ratio of IGF-1R:IR binding affinity59,64
and the IR residency time58,59 of insulin analogs 
each correlate with mitogenic potency in cell 
models expressing the relevant receptors. The 
evidence suggested that the relationship between 
relative IGF-1R affinity and mitogenic potency 
is continuous, whereas increased mitogenic 
potency only manifests when IR off-rate declines 
below ~40% that of human insulin.58 Thus, the 
analog development program at Novo Nordisk, 
where X10 had been constructed and studied, 
incorporated the criteria that any analog to be 
brought into clinical development should have 
an IGF-1R:IR affinity that does not exceed that 
of human insulin, and should have an IR off-rate 
not markedly lower than that of human insulin. 
Whether IGF-1R affinity is of greater concern 
than increased IR residency time is unknown, 
but one in vitro study has suggested that the 
IGF-1R-mediated proliferative effect predominates 
in human fibroblasts.65 Here, silencing of IGF-1R 
significantly blunted ligand-mediated stimulation 
of Akt phosphorylation by IGF-1, X10, and insulin 
glargine (by 72%, 58%, and 40%, respectively), 
while the insulin-mediated response remained 
unaffected. In contrast, silencing of IR did 
not significantly alter Akt phosphorylation in 
response to IGF-1, X10, or glargine.
Figure 1. (A) Insulin receptor (IR) off-rate and (B) insulin-like growth factor (IGF-1) receptor:IR binding affinity for 
various insulin-like ligands, with values expressed as percentages of human insulin. Adapted with permission from Kurtzhals  
et al. Diabetes 2000. 
Point below which analogs become mitogenic. 
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Two epidemiological studies have been 
published based on insulin analog manufacturers’ 
databases. A meta-analysis of 31 randomized 
controlled clinical trials, comparing insulin 
glargine with any comparator in T1DM or 
T2DM,66 did not find an increased risk of cancer 
with glargine versus comparator treatment in 
any study, with the comparator being NPH 
insulin in 21 studies. A second meta-analysis of 
16 randomized trials (>12 weeks) involving 8693 
patients with T1DM or T2DM compared insulin 
detemir with either NPH or insulin glargine.67
Here, insulin detemir was not associated with an 
increased risk of cancer compared with NPH or 
glargine (events/100 years: 0.36, 0.92, and 1.27, 
respectively; not significant). 
Discussion Points Arising
The greatest limitation of the glargine and 
detemir meta-analyses was the short time-
scale of the included studies. The Outcome 
Reduction with Initial Glargine Intervention 
(ORIGIN) study68 will provide data for >10,000 
patient-years of exposure to glargine in the 
absence of metformin, but even this might be 
underpowered to detect even a 30% difference 
in cancer risk. Of course, this study was not 
designed to evaluate this endpoint. A large-scale 
International Strategic Cancer Alliance study on 
breast cancer might also provide new data on 
associations with diabetes and insulin use.
PRINCIPLES FOR INSULIN ANALOG 
DEVELOPMENT 
Bo Falck Hansen 
The hypothesis that mitogenesis might at least 
in part be mediated via IGF-1R binding, and 
early reports59 that insulin glargine had an 
approximately six-fold increase in affinity for 
IGF-1R (and an approximately nine-fold increase 
in IGF-1R:IR affinity ratio) compared with 
human insulin led to the original epidemiologic 
enquiry by Hemkens et al1 and the associated 
confirmatory studies.2-4 These in turn have led to 
a spate of more recent in vitro studies revisiting 
the receptor binding and mitogenic properties of 
insulin analogs, and applying different models 
and methodological techniques. However, 
to interpret the findings of these studies, 
it is important to consider some principles 
of investigation that have been previously 
highlighted,69 but which have been overlooked 
in several in vitro studies. 
Firstly, it is important to realize that the 
relative potencies of different insulin analogs for 
given metabolic or mitogenic effects can only 
be determined from full dose-response curves.69
An insulin-like molecule is likely to have at 
least some affinity for both IR and IGF-1R, so 
is potentially able to exert anything from zero 
to full response in cells carrying one or both 
receptor types, depending on its concentration 
(Figure 2).69 Thus, comparisons of different 
Figure 2. Representative dose-response curves, with shapes 
typical of insulin-like ligands. Black dotted double-headed 
arrow indicates the constant difference between two ligands 
of high (solid black) and low (dotted black) potency across 
the responsive part of the dose-response curve. Grey arrows 
illustrate how the use of fixed doses could be misconstrued 
to suggest either a large (left) or small (right) response 
difference between the ligands. Adapted with permission 
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ligands made at either very high doses (at which 
they are all exerting a maximum effect), or very 
low doses (at which they are exerting little or 
no effect) are unlikely to show differences, and 
consequently have little value. Instead, full 
dose-response curves should be constructed. 
If the curve is shifted to the left relative to 
human insulin (ie, the response commences and 
maximizes at lower concentrations), then this 
ligand has greater potency for the response in 
question. Conversely, a rightward shift indicates 
reduced potency. Relative potencies can then 
be compared in terms of median effective 
concentration (EC50) values. 
Potency alone, however, is still insufficient 
to indicate the mitogenic potential of an analog 
in vivo, as insulin-like ligands vary greatly in 
their absolute affinities for receptors. Therefore, 
even EC50 values from full dose-response 
curves are potentially misleading and, when 
considering the potential for IGF-1R-mediated 
mitogenicity in receptor-binding studies, what 
is important is the ratio of effect that a ligand 
has for IGF-1R:IR binding/activation potency 
or its mitogenic:metabolic potency and how 
this ratio compares with human insulin 
(Figure 1). These ratios might determine the 
likely in vivo proportions of binding among 
the various potential receptors available to the 
ligand, and hence the likely biologic effects in 
the organism. 
Another pitfall  when investigating 
mitogenicity in in vitro experimentation is to use 
cell types that are poorly responsive or (worse) 
do not carry appropriate receptors. Such cells will 
inevitably fail to show differences in mitogenic 
response between one ligand and another, and 
could give false reassurance. Suspicion is called for 
if positive controls, such as the known mitogens 
X10 and IGF-1, fail to show substantially greater 
mitogenic responses than human insulin and/or 
the study ligands (Figure 3).70,71
Figure 3. Importance of cell type, receptor expression and 
ligand dose in evaluating mitogenic potency of insulin 
analogs. (A) No difference in proliferation is seen between 
insulin analogs across a range of doses when they are added 
to the culture of cells expressing relatively few insulin-like 
growth factor receptor 1 (IGF-1R), whereas (B) insulin 
glargine shows an increased proliferative response in cells 
expressing relatively many IGF-1R. MCF=Michigan 
Cancer Foundation. Reproduced by permission from 
Shukla et al. 200970 © Society for Endocrinology 2011. 
(C) Embryonic mouse fibroblasts expressing IGF-1R and 
exposed to a single concentration of the study ligands  
(5 nmol/L for all except insulin detemir given at 19 nmol/L). 
Note that IGF-1 evokes only an approximately 30% greater 
response than human insulin at this dose in this cell system. 
Reproduced with permission from Sciacca et al. Diabetologia. 
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If the hypothesis is that analogs with an 
increased IGF-1R:IR affinity relative to human 
insulin might accelerate tumor growth, then 
testing this will require use of cells expressing 
abundant IGF-1R that respond by exhibiting 
proliferation. Predictably, those studies that have 
not shown differences between insulin glargine and 
other insulins in terms of binding affinities and/or 
mitogenic effects have tended to use incomplete 
dose-response curves71-73 and/or unresponsive 
cell lines, in which IGF-1 itself showed relatively 
little increase in potency/effect size versus the 
comparators or human insulin.71-75 In contrast, 
studies using complete or near-complete dose-
response curves and/or responsive cells expressing 
IGF-1R have tended to confirm the earlier work 
of Kurtzhals and colleagues59 in suggesting that 
insulin glargine has a greater IGF-1R:IR affinity 
ratio than human insulin, with greater mitogenic 
potency mediated via IGF-1R.70,76-78
One study by Hansen and colleagues78 has 
been undertaken in an attempt to redress the 
inconsistencies of other recent publications, 
by constructing full dose-response curves to 
make a comprehensive series of comparisons of 
insulin glargine, insulin detemir, and human 
insulin with regard to receptor interactions 
and mitogenic responses. This study compared 
the ligands’ IR and IGF-1R binding affinities, 
regional receptor phosphorylation, and receptor 
activation kinetics, as well as mitogenic potential 
in two different cell types chosen because they 
predominantly express either IR or IGF-1R. 
The study also examined the ligands’ relative 
affinity and activation of IR-A and IR-B. This is 
significant because it can be speculated that a 
greater potency for IR-A versus IR-B activation 
(relative to human insulin) could also increase 
the mitogenic risk associated with an insulin 
analog.71,79 In summary, this work confirmed 
earlier studies by the groups of Kurtzhals59
and Sommerfeld,76 by showing that insulin 
detemir was not associated with an increased 
IGF-1R:IR binding ratio, or prolonged IR 
residency, whereas insulin glargine displayed an 
increased IGF-1R:IR binding ratio, but also did 
not have prolonged IR residency. None of the new 
receptor interaction characteristics examined for 
detemir and glargine was found to be different 
from human insulin, consistent with a recent 
study by Varewijck and colleagues,77 based on 
partial dose-response curves. When cultured 
with cells (L6-hIR) expressing abundant IR, 
neither glargine nor detemir evoked an increased 
proliferative response relative to human insulin 
(whereas the effect of X10 was increased). When 
the ligands were applied to cells expressing 
abundant IGF-1R (human mammary epithelial 
cells [HMEC]), the proliferative response was 
increased with glargine (and X10), but not with 
detemir relative to human insulin. These data 
therefore suggest that any increased mitogenic 
effect of insulin glargine is likely to be mediated 
via IGF-1R (or IR/IGF-IR hybrids). 
Although insulin glargine shows an increased 
affinity for IGF-1R and increased mitogenic 
potential in several in vitro models, it must be 
noted that there are no in vivo data to show that 
this property translates into an increased risk 
of incident cancer (or an adverse prognosis in 
established cancer). Furthermore, although well-
conducted in vitro studies can show up differences 
between insulin-like ligands in their receptor 
interaction profiles and in the responses they 
evoke in isolated cell cultures, the extrapolation 
of these data into clinical consequence is fraught 
with difficulties. Clearly, further study is required 
and better models are needed with which to test 
insulin analog safety. It has been argued that 
animal models will potentially provide much 
better test systems than cell cultures, and ideally 
these should also be models of human diabetes.69
In such systems, the relative effects of study 
ligands will be mediated and mitigated through 
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a similar constellation of confounding factors 
to those seen in patients with diabetes, such as 
ligand distribution and kinetics, endogenous 
endocrine factors, adiposity, insulin resistance, 
etc. The rate of tumor growth in the setting of 
different insulin (or other) treatments in animals 
with chemically induced, implanted allograft, 
or xenograft tumors could be informative. The 
in vivo influence of ligands on transgenic tissue 
over-expressing receptors such as IGF-1R is 
another possibility. Such models will potentially 
enable clinically relevant data to be generated 
within practical timescales.
Discussion Points Arising
One appealing aspect of diabetic animals as test 
models is that they are less likely to be vulnerable 
to hypoglycemia, which has prevented the rodent 
toxicology study that showed an increase in cancer 
risk with X10 from being repeated for long-acting 
insulins. It is important that such models should be 
able to show a difference between no administration 
of a ligand, human insulin, and X10.
Concerning whether hyperglycemia would 
create a more representative environment in 
an animal model, it was noted that positron 
emission tomography scanning shows some 
cancer cells to be extremely efficient at loading 
glucose independently of insulin, with hypoxia 
being a powerful stimulus. This was not true of 
all cancer cells, however, with glucose uptake 
only detected for some when insulin is given.
MEETING CONCLUSION AND 
CONCLUDING DISCUSSIONS 
Stephen Gough
Despite there being a growing knowledge 
base that should inform future discussions 
and research directions, current gaps in our 
understanding and different viewpoints about 
how to interpret available data do not allow a 
consensus to be reached on how to advise the 
use of diabetes treatment options, or indeed on 
how best (or whether) to discuss the issue with 
patients to reach an ‘informed choice.’ The 
subject of how diabetes and its treatments affect 
cancer is complicated, and the numerous factors 
involved in the complex signaling networks 
influencing mitogenic responses, are difficult 
to tease apart. Putative new animal models 
are likely to be valuable and informative tools 
that will help to bridge the gap from laboratory 
work to clinical predictions. Although some 
such models have been proposed, including 
induced tumor, transplanted tumor, and 
transgenic models (IGF-1R over-expression in 
breast tissue), these have yet to be developed 
into fully mature systems. 
Further clinical data, however, are also 
required, hence there remains a need to study 
the responses of human tumors to different 
growth factor ligands, and to study the 
effects of ligands on biomarkers of neoplasm 
in humans. Epidemiologic study of patients 
with diabetes and family histories of cancer or 
precancerous lesions (eg, colonic polyps) could 
also provide important data, and there is a 
need to identify any genetic predispositions to 
cancer that might affect therapy choices. There 
might also be a ‘surgical window’ that could 
be exploited to study the influence of diabetes 
therapies: the growth of benign tumors could 
be studied in patients with diabetes awaiting 
surgical removal of their tumor. As the 
American Diabetes Association is insisting on 
the capture of cardiovascular outcome data for 
new diabetes therapies, an opportunity also 
exists to routinely capture cancer data in new 
clinical studies.
Finally, the insulin/IGF axis and its interplay 
with physiological states in both patients with 
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diabetes and those individuals with other 
morbidities span many disciplines. It is therefore 
clear that greater cooperation and communication 
between diabetologists, epidemiologists, 
oncologists, and insulin engineers will be 
essential if we are to fully understand how 
peptide hormones can affect cancer risk. Such an 
understanding should facilitate the engineering 
of future treatments that are designed to strike 
the most optimal balance between therapeutic 
efficacy and molecular safety.
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